Clinical trials
catalyst calendar across sponsors →Studies where HAE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 8 observational · 4 with posted results
Held by 17 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, ARIEL INVESTMENTS, LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Holocene Advisors, LP, +12 more) · FINRA short interest 4.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH CartridgeNCT06352125observationalPrimary Method Comparison | — | Completed | Diagnostic test: TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen | Surgery | 338 | 2023-01-31actual | 2024-04-08 |
| Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy VolunteersNCT06261580observationalCK-MA TEG Parameter | — | Completed | Diagnostic test: TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen | Healthy | 181 | 2021-10-25actual | 2024-02-15 |
| IMPACT (Improving Plasma Collection) Clinical TrialNCT04320823results2021-04-09Rate of Significant Hypotensive Adverse EventsRandomized · Triple-masked · OtherStatistical Analysis Plan ↗ · Study Protocol ↗ | Not applicable | Completed | Device: Updated Plasma Collection Feature, Current Plasma Collection Approach | Apheresis Related Hypotension | 3,443 | 2020-03-27actual | 2021-04-09 |
| Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S SystemNCT02798328observationalPresence / Absence of DOAC Drug | — | Completed | Device: TEG6s DOAC Cartridge | DOAC Eligible Subjects | 385 | Sep 2017actual | 2020-02-11 |
| Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube HolderNCT02476851results2022-04-29Plasma Supernatant HemoglobinRandomized · Open-label · Other | Not applicable | Completed | Device: POLFA (Needle Assembly), Kawasumi (Needle Assembly) | Transmission, Blood, Recipient/Donor | 62 | Jul 2015actual | 2022-04-29 |
| Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive SolutionNCT02145507results2022-03-28Red Blood Cell Post-filtration RecoveryRandomized · Open-label · Supportive care | Phase 1 | Completed | Drug: SOLX (Investigational), AS-3 (Control) | Blood Donors | 170 | Dec 2014actual | 2022-04-25 |
| Procedure For The Reference Range Study For Absolute MANCT02110576observationalTEG Reference Ranges | — | Completed | — | Transmission, Blood, Recipient/Donor | 161 | Sep 2014actual | 2015-04-03 |
| Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)NCT01764061observationalHemolysis level at 42 days of storage | — | Completed | — | Red Blood Cell Donation | 60 | Sep 2013actual | 2013-10-11 |
| Clinical Evaluation of the OrthoPAT Advance SystemNCT01756976results2013-11-20observationalWashed RBC Hematocrit | — | Completed | Device: OrthoPat Advance | Transmission, Blood, Recipient/Donor | 84 | Aug 2013actual | 2013-11-20 |
| RapidTEG MA ValidationNCT01428102observationalCorreelation of Kaolin to RapidTEG | — | Terminatedsponsor's stated reason: Terminiated for trial redesign | — | Coagulation, Platelet Function | 17 | Oct 2012actual | 2013-09-16 |
| Thromboelastography (TEG) Reference Range StudyNCT01357928observational | — | Completed | — | Coagulation | 159 | Jul 2011actual | 2012-09-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19